START FREE TRIAL
Home Healthcare Glaukos Corporation

Glaukos Corporation

$19.00

SKU: GKOS-1 Category:

Description

Glaukos’ $76 Million iDose TR Franchise — Can Medicare Coverage Disrupt Growth?

 

Glaukos Corporation reported strong financial results for the third quarter of 2026, highlighted by record consolidated net sales of $211 million, representing a 58% increase compared to the same period last year. This performance led the company to raise its full-year 2026 sales guidance to a range of $775 million to $785 million, up from prior expectations of $680 million to $700 million. Additionally, Glaukos provided a preliminary revenue outlook for 2027 at approximately $1 billion, reflecting optimism about the commercial rollout of its key products, Epioxa and iDose TR, alongside its International Glaucoma franchise. The Corneal Health segment, driven primarily by Epioxa—an FDA-approved epithelium-on corneal cross-linking therapy for keratoconus—delivered record sales of $59 million, a growth of 154% year-over-year. The company emphasized progress in expanding its site-of-care network, which currently serves about 90% of the U.S. population with plans to increase further.